Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2608204, Glimepiride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lancaster, California • Spring Valley, California + 15 more

Conditions: Lung Cancer
Interventions: celecoxib, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 44
States / cities: Colorado Springs, Colorado • Gainesville, Florida • Jacksonville, Florida + 37 more

Conditions: Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
Interventions: NBI-827104, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Pruritus, Psoriasis
Interventions: SNA-120, Placebo, Calcipotriene; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more

Conditions: Type 1 Hyperlipoproteinemia
Interventions: SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Endometrial Cancer
Interventions: BN83495; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Augusta, Georgia • Minneapolis, Minnesota • Philadelphia, Pennsylvania + 1 more

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Brain and Central Nervous System Tumors
Interventions: celecoxib, temozolomide, thalidomide, adjuvant therapy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: rosiglitazone, metformin, PN2034; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 21 Years to 72 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more

Conditions: Cutaneous Lupus Erythematosus
Interventions: Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Tiopronin, Placebo; Drug
Lead sponsor: E. Sander Connolly; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Gainesville, Florida • New York, New York • Seattle, Washington

Conditions: Postoperative Wound Infection-deep, Post Operative Wound Infection
Interventions: RUT058-60, Sterile saline for irrigation; Drug
Lead sponsor: Pulmatrix Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Mobile, Alabama • La Jolla, California • Houston, Texas + 1 more

Conditions: Tumors
Interventions: Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Osteomyelitis
Interventions: Dalbavancin, Standard of Care; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Ft. Pierce, Florida

Conditions: Kidney Cancer
Interventions: PEG-interferon alfa-2b, gefitinib; Biological · Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Sacramento, California

Conditions: COVID-19 Disease
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 23
States / cities: Chandler, Arizona • Newport Beach, California • Sacramento, California + 19 more

Conditions: Tuberculosis
Interventions: Imatinib, Isoniazid, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Rituximab (RTX), Tafasitamab, Bendamustine (BEN); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 18
States / cities: Anaheim, California • Bakersfield, California • Burbank, California + 15 more

Conditions: Neoplasms
Interventions: GSK3326595, 5-Azacitidine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more

Conditions: Brain Tumors, Central Nervous System Tumors, Leptomeningeal Metastases
Interventions: temozolomide; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer.
Interventions: G-202; Drug
Lead sponsor: GenSpera, Inc.; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glioblastoma Multiforme
Interventions: Bevacizumab and Temozolomide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Atopic Dermatitis
Interventions: Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • Hialeah, Florida + 14 more

Search by objective public record fields.

A Study in Patients With Type 2 Diabetes

Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer

Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis